2026/01/16 by Jin Li, Jinlong Hu, Chunwei Xu +96 · 1 voice
Medicine · #Occupational and environmental lung diseases #Intraperitoneal and Appendiceal Malignancies #Pleural and Pulmonary Diseases
paper · pdf · doi:10.65364/iomj.2026.01
openalex publication_date 2026/01/16 · openalex created_date 2026/01/17 · openalex updated_date 2026/07/21
Malignant peritoneal mesothelioma (MPeM) is a malignant tumor originating from the peritoneum. In recent years, the incidence of MPeM has been increasing. Because MPeM is insidious in onset and of strong local invasiveness, and most patients are found in advanced stage, early screening and treatment of the population at the high risk of malignant mesothelioma are of vital importance. The main treatment methods for MPeM include cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, systemic chemotherapy and immunotherapy. To promote the homogenization and normalization of the diagnosis and treatment of malignant peritoneal mesothelioma, based on existing clinical research evidence, the Chinese Alliance of Research for Mesothelioma (ChARM) formulated the National Expert Consensus on the Clinical Diagnosis and Treatment of Malignant Peritoneal Mesothelioma in combination with expert opinions nationwide. The contents of expert consensus cover epidemiology, diagnosis, treatment and prognosis follow-up.